No Benefit of Ipatasertib + Paclitaxel for PIK3CA/AKT1/PTEN-Altered HR+/HER2− Advanced Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial
Breast Cancer Res Treat 2021 Dec 03;[EPub Ahead of Print], N Turner, RA Dent, J O'Shaughnessy, SB Kim, SJ Isakoff, C Barrios, S Saji, I Bondarenko, Z Nowecki, Q Lian, SJ Reilly, H Hinton, MJ Wongchenko, B Kovic, A Mani, M OliveiraFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.